BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30422368)

  • 21. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
    Ward RM; Tammara B; Sullivan SE; Stewart DL; Rath N; Meng X; Maguire MK; Comer GM
    Eur J Clin Pharmacol; 2010 Jun; 66(6):555-61. PubMed ID: 20306184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.
    Maejima R; Koike T; Nakagawa K; Iijima K; Shimosegawa T
    Tohoku J Exp Med; 2015 Mar; 235(3):249-53. PubMed ID: 25786769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of esomeprazole for treatment of poorly controlled asthma.
    ; Mastronarde JG; Anthonisen NR; Castro M; Holbrook JT; Leone FT; Teague WG; Wise RA
    N Engl J Med; 2009 Apr; 360(15):1487-99. PubMed ID: 19357404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
    Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of esomeprazole in patients with hepatic impairment.
    Sjövall H; Björnsson E; Holmberg J; Hasselgren G; Röhss K; Hassan-Alin M
    Eur J Gastroenterol Hepatol; 2002 May; 14(5):491-6. PubMed ID: 11984146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.
    Sun J; Yuan YZ; Hou XH; Zou DW; Lu B; Chen MH; Liu F; Wu KC; Zou XP; Li YQ; Zhou LY
    World J Gastroenterol; 2015 Jun; 21(22):6965-73. PubMed ID: 26078574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
    Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
    Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
    Parekh PJ; Oldfield EC; Johnson DA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
    Cicali EJ; Blake K; Gong Y; Mougey EB; Al-Atrash H; Chambers N; Denham J; Evans J; George DE; Gomez R; Palomo P; Taufiq S; Johnson JA; Lima JJ; Franciosi JP
    Clin Transl Sci; 2019 Mar; 12(2):172-179. PubMed ID: 30341969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetic properties of esomeprazole in children aged 1 - 11 years with endoscopically proven GERD: a randomized, open-label study.
    Youssef NN; Tron E; Tolia V; Hamer-Maansson JE; Lundborg P; Illueca M
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):965-72. PubMed ID: 25250612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose esomeprazole is required for intraesophageal acid control in gastroesophageal reflux disease patients with hiatus hernia.
    Peng S; Xiao YL; Cui Y; Lin JK; Zhang N; Hu PJ; Chen MH
    J Gastroenterol Hepatol; 2012 May; 27(5):893-8. PubMed ID: 22098387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous esomeprazole.
    Keating GM; Figgitt DP
    Drugs; 2004; 64(8):875-82; discussion 883. PubMed ID: 15059043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):530-7. PubMed ID: 18030229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.